Binnopharm Group’s Retail Sales Grow 11% in April

In April 2026, Binnopharm Group increased its retail sales by 11% year-on-year to RUB 4.5 billion. The company’s pharmacy sales growth outpaced the overall pharmaceutical market, which grew by 8% during the month, according to AlphaRM. At the end of April, Binnopharm Group’s share of the Russian pharmaceutical market stood at 2.4%.

In the first four months of 2026, Binnopharm Group’s pharmacy sales exceeded RUB 18.5 billion, up 4% compared with the same period in 2025. Tender sales increased by 45% to RUB 2.9 billion.

«Since the beginning of the year, Binnopharm Group has maintained its sixth position in Russia’s retail pharmaceutical market. In April, the company managed to outperform the market growth rate thanks to its balanced product portfolio and strong positions in key therapeutic categories», said Igor Bakhmetyev, commercial director of Binnopharm Group.

Since the beginning of the year, the strongest sales growth in value terms was recorded for an anti-inflammatory gel, with sales increasing by RUB 245 million to RUB 1.25 billion; an antispasmodic for gastrointestinal disorders, up RUB 171 million to RUB 1.19 billion; and a choleretic drug, up RUB 97 million to RUB 537 million.